Objectives: Paroxetine has been reported to be useful for management of stuttering symptoms, but only a few reports have examined its effects. We have investigated the efficacy of paroxetine in a randomized, placebo-controlled study.
D evelopmental stuttering is characterized by sound and syllable repetition at the beginning of words and sentences, in addition to sound prolongation, interruptions, silences or sound blocks, facial spasms, and muscular tensions in the orofacial district during speech. 1 Behavioral approaches are the principal means of intervention in stuttering, but pharmacological intervention is increasingly considered as well. 2 In fact, a large number of experimental studies have suggested that the neurological component may play a very important role in stuttering. 3Y5 Nevertheless, neurobiological mechanisms of developmental stuttering remain poorly understood. Available results allow the hypothesis 5 that developmental stuttering might be considered as a mainly neurological dysfunction and more specifically as a dopaminergic dysfunction of the basal ganglia. This hypothesis is indirectly confirmed by the efficacy of antidopaminergic drugs, 6Y9 which may be useful in controlling stuttering symptoms. However, they could be associated with severe side effects, especially after haloperidol administration. 6 It has been suggested that, in the brain, the neurotransmitter balance as a whole, and not just a quantitative variation of a single neurotransmitter, is fundamental for the smooth execution of speech. 10 In this sense, some studies have documented the use of selective serotonin reuptake inhibitor drugs 11Y13 in the treatment of stuttering.
Reports that paroxetine is effective for the treatment of stuttering are largely based on case studies, 11, 12 and severe side effects have not been observed. In contrast, the only larger study with paroxetine on stuttering showed no beneficial effects on stuttering symptoms, and side effects were also observed. 14 The present study assessed the efficacy of paroxetine in managing the stuttering symptoms, in a small sample of voluntary patients. Both quantitative and qualitative measures of speech fluency were obtained, and cortical excitability of the left primary motor cortex of stutterers was measured using transcranial magnetic stimulation (TMS).
MATERIALS AND METHODS
Eight stuttering volunteers (age range, 19Y43 years; mean, 28.8 years [SD, 7.9 years]) were recruited for the study.
Subjects were screened for the possibility of taking paroxetine with a low risk of side effects. Successively, experimental procedures were explained, and an informed consent was signed allowing subjects to leave the experiment at any point. There were no dropouts, and paroxetine was always well tolerated. Permission from the local ethics committee was obtained, and all procedures were carried out in accordance with the Declaration of Helsinki. Subjects were randomly assigned to 2 groups.
In the first group (n = 5; age range, 26Y34 years; mean, 29.8 years [SD, 3.7 years]), paroxetine (20 mg once daily at night) was administered for 12 weeks. In the second group (n = 5; age range, 19Y43 years; mean. 29.2 years [SD, 10.0 years]), a placebo was administered for the same period.
Two subjects, participating first in the placebo group, crossed over to the paroxetine group. Four subjects had undergone some type of previous speech therapy, but not during the last year. None of the subjects had previously attempted pharmacological therapy for stuttering. All measurements were recorded at baseline and after 6 and 12 weeks of treatment.
Fluency Measurements
Stuttering was assessed through standardized conversations with the same interviewer, who asked each subject to describe life events. Subjects also read a text of about 200 words, different in content for every period of examination. All sessions were audiotaped and videotaped to obtain the Stuttering Severity Instrument (SSI) score. 15 The percentage of stuttered words was obtained by averaging the spontaneous speech task score and the reading passage task of the SSI, both based on a speech sample of 100 words.
Stuttering Associated Movements During Speech Evaluation
A sample of 400 words was extracted from the standardized conversation to conduct a simplified evaluation of stutteringassociated movements during speech after every period-based examination as described by Mulligan et al. 16 The appearance of involuntary movements was considered in the superior and inferior face muscular districts, in addition to all types of head, arm, and torso movements. The superior face muscular district consisted of 3 categories (repetitive and prolonged eye blinks, eyebrow movements, and looking-around movements), whereas 2 categories were identified for the inferior face muscular district (repetitive and prolonged jaw tremors and unnatural movements and positions of mouth district related to speech articulation). To avoid being influenced by stuttering episodes, audio was excluded while the recordings were evaluated. No distinction was made between simple and complex involuntary movements. Head-shakings with a potential Byes[ or Bno[ meaning were discarded, as the actual intent of the subject was not considered without audio support. Furthermore, involuntary movements not associated with speech production during the recording session were also discarded, as they were not related to proper speech articulation and not necessarily related to stuttering episodes.
Transcranial Magnetic Stimulation Measures
Transcranial magnetic stimulation allows measures as the resting motor threshold (RMT) or active motor threshold (AMT), related to membrane potential properties of cortical and spinal motor neurons, 17Y21 or cortical silent period (CSP), a transient suppression of muscular activity after depolarization of motor neuronal populations, which represents the level of intracortical inhibition, at least in its latter phase. 22, 23 During TMS, subjects were comfortably seated, and surface electromyographic electrodes were applied on the first dorsal interosseous (FDI) muscle of the right hand. A tissue cap, with points distant 1 cm and forming a grid, was applied on the head to individuate the Cz point according to the 10Y20 EEG International System. Experimental procedures were conducted using a focal 8-shaped coil (each wing measuring 7 cm). Transcranial magnetic stimulation coil was positioned by pointing the handle backward and 45 degrees lateral from the midline. The hot spot for FDI was individuated by stimulating the left hemisphere motor cortex moving in steps of 1 cm until the best representation point was individuated. The AMT was obtained by asking the subject to keep a pen in his/her hand without pressing to evoke the FDI preactivation. The RMT and AMT corresponded to the TMS intensity that evoked Motor Evoked Potentials (MEPs) of at least 50 KV in 5 of 10 consecutive stimulations.
The CSP was obtained by asking the subject to maintain the maximal FDI contraction and registering 10 consecutive pulses (100 milliseconds before and 400 milliseconds after stimulus) on the best cortical FDI representation with a TMS intensity corresponding to RMT. Subjects were permitted a resting period between 2 successive pulses to prevent fatigue. We considered single silent periods as valid when the amplitude was lower than 20 KV for the complete duration (starting and ending points included). 
Statistical Analysis
Descriptive statistics were provided using means and SDs. Statistical inference in normally distributed data was approached with Fisher F test and subsequently by t test; in abnormally distributed data, the Wilcoxon Mann-Whitney nonparametric test was used.
Poisson distributed generalized linear models were used to investigate covariates. Group affiliation (paroxetine vs placebo group) and period of examination (baseline, 6 or 12 weeks) were considered as main factors in fluency, motor thresholds, and silent period analyses. In stuttering-associated movement analysis, categorization of muscular districts related to movements (superior face muscular district, inferior face muscular district, head or arm/torso) was considered in addition to group affiliation and period of examination as main factors.
Statistically significant interactions were considered in a model backward simplification process.
Data from fluency measurements were expressed as percentage, and motor threshold values were expressed as percentage of the maximum stimulator output, whereas CSP data were expressed in milliseconds. Data from stuttering-associated movements during speech were expressed as frequencies. In all instances, a level P G 0.05 was considered significant.
RESULTS

Fluency Analysis
In the paroxetine group, the SSI classified 2 stutterers as severe at baseline, who were reclassified as severe and moderate after 6 weeks of treatment, and as moderate and severe after 12 weeks of treatment, respectively. Three stutterers were classified as moderate at baseline: of these, 2 were indicated as moderate and 1 as mild after 6 weeks of treatment, and 3 as mild after 12 weeks of treatment. In the placebo group, the SSI classified 1 stutterer as severe at baseline, whereas at 6 and 12 weeks of treatment, that stutterer was classified as moderate. Two stutterers were identified as moderate at baseline, whereas after 6 and 12 weeks of treatment, they were moderate and mild, respectively. Finally, 2 stutterers were classified as mild and very mild at baseline, which was confirmed after 6 and 12 weeks of treatment ( Table 1 ). The percentage of stuttered words showed a greater improvement in the paroxetine group than in the placebo group, although statistical analyses showed no significant differences ( Table 1) .
Stuttering-Associated Movements Analysis
Analysis of stuttering-associated movements during spontaneous speech showed that all main factors were statistically significant (group affiliation: P G 0.001; period of examination: P G 0.001; muscular districts: P G 0.001), indicating that the paroxetine group had a total number of associated movements greater than the placebo group, that associated movements tended to decrease during treatment, and that they are quantitatively different in relation to different muscular districts ( Table 2) .
Significant interactions between group affiliation and the period of examination and between muscular districts and the period of examination were found (P G 0.001 and P G 0.001, respectively), indicating that the paroxetine and placebo groups may have been differently affected by the treatment in relation to the different muscular districts. In fact, a significant interaction between all main factors was also found (P = 0.003). Backward simplification showed a significant interaction between categorization of muscular districts and the period of examination both in the paroxetine (P G 0.001) and in the placebo group (P = 0.009). However, Wilcoxon signed rank sum test showed the existence of significant differences only in the paroxetine group between baseline and 6 weeks of treatment, and between baseline and 12 weeks of treatment in relation to superior face muscular districts (P = 0.032 for both comparisons), indicating a reduction of associated movements in relation to the treatment (Fig. 1A) . Moreover, significant differences were found between baseline and 6 weeks of treatment, between baseline and 12 weeks of treatment, and between 6 weeks and 12 weeks of treatment in relation to inferior face muscular districts in the paroxetine group (P = 0.032, P = 0.029, P = 0.021, respectively), indicating a reduction of associated movements in relation to the treatment (Fig. 1B ). Significant differences were also observed in the placebo group when considering inferior face muscular districts. Comparison between baseline and 6 weeks of treatment and between baseline and 12 weeks of treatment showed a trend toward significance (P = 0.05 for both comparisons), whereas comparison between 6 and 12 weeks of treatment was statistically significant (P = 0.017). In the latter case, the significant difference indicated an increase in associated movements after 12 weeks of treatment.
TMS Analysis
Analyses revealed significant effects of group affiliation and period of examination in the CSP (P = 0.04 and P G 0.001, respectively), and a significant interaction was found between the period of examination and group (P G 0.001). Wilcoxon signed rank sum test indicated a significant difference between baseline and 6 weeks of treatment, between baseline and 12 weeks of treatment, and between 6 and 12 weeks of treatment in the paroxetine group (P = 0.032 for all comparisons), indicating a statistically significant decrease in the silent period after paroxetine administration (Table 3 and Fig. 2 ). No significant differences were observed in the placebo group covariates. Transcranial magnetic stimulation evoked no statistical differences between the paroxetine and placebo groups in either RMT or AMT.
DISCUSSION
Facial stuttering-associated movements during speech and CSP were significantly reduced by paroxetine administration compared with placebo. This reduction was evident in the superior facial muscular districts, and a time-related reduction was also found for inferior facial muscular districts. This may be in strict relation with difficulties in speech production, indicating a qualitative decrease in stuttering severity. In fact, no improvement was evident considering the percentage of speech disfluency compared with the placebo group. Consequently, paroxetine, in the 12 weeks of treatment, might principally act on the qualitative aspects of stuttering, as measured by associated movements during speech, more than on its quantitative aspects, as measured by speech disfluency.
Compared with previous findings, the present investigation confirms that stuttering-associated movements during speech can be considered a genuine part of the syndrome, 16 and not only a secondary symptom. 24Y26 In fact, paroxetine reduced stuttering symptoms, whereas any effect on the quantity of speech disfluency was less pronounced.
Paroxetine has been suggested to improve motor performance in healthy humans, presumably by an increase in motor cortex excitability and/or a decrease in intracortical inhibition. 27, 28 Considering the present data, a statistically significant reduction in CSP was found only in the paroxetine group. A reduction in CSP may be positively related with the duration of the treatment, and it could be also correlated with the reduction in stuttering-associated movements during speech. In fact, a diminution in cortical and/or intracortical inhibition of stutterers' primary motor cortex may reduce speech difficulties and, consequently, the number of associated movements during speech.
The significant shortening of the silent period in the paroxetine group may indicate that this parameter is affected in stuttering syndrome and that paroxetine could help to restore it. Shortening of the silent period was also significantly greater after 12 weeks of treatment than after 6 weeks, suggesting additional benefits of paroxetine with time. The CSP has been previously reported to mainly represent the level of intracortical inhibition, at least in its latter phase, 22, 23 although cortical influences on the silent period have also been suggested. 29 Spinal mechanisms have been reported to influence the CSP in its early phase, 30 whereas there are also reports suggesting a full cortical origin of this parameter. 31, 32 Consequently, a deficit in intracortical inhibition, at least in the left hemisphere, can be hypothetically associated to stuttering. Present findings suggest that this deficit may be related to speech disfluency and, overall, to more general motor symptoms in stuttering, as, for example, associated movements during speech. 16 In conclusion, we show that 12 weeks of paroxetine administration may reduce the primary motor cortex inhibition in stutterers and qualitative aspects of speech difficulties in stuttering, as shown by stuttering-associated movements during speech. Such reductions may also be time-dependent. It is therefore possible that a strict relation between the 2 events exists.
The present study sheds light on the effectiveness of paroxetine in stuttering, although the results should be still considered preliminary and require confirmation. The fact that this trial was not conducted in a double-blind manner could have biased the results, and a longer study period would be desirable. Nonetheless, paroxetine should be considered as a possibility for pharmacological intervention in stuttering when behavioral speech therapies fail to benefit stuttering management and/or when antidopaminergic drugs 7Y9 with documented benefits are not well tolerated by the patient.
